Barbara Laughon NIAID, NIH Report of TB/HIV Diagnostics Task Force.

Slides:



Advertisements
Similar presentations
Diagnosis of AFB Smear- Negative Pulmonary TB in HIV- Infected Persons Richard OBrien Foundation for Innovative New Diagnostics (FIND)
Advertisements

Implementing a TB-Control Program in Prisons: The Basics Dr. Mayra Arias.
ISTC Training Modules 2008 Your name Institution/organization Meeting Date.
Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.
Agenda Background Current testings Xpert MTB/RIF product PAGE | 1.
New Technologies for Tuberculosis Control: Programme Perspective Draft Definitions Retooling Task Force Meeting Geneva, Switzerland January 2008.
Improving diagnosis TB laboratory strengthening.
Retooling Task Force. Liquid Media for Culture and Drug Susceptibility Testing Generic checklist for TB Diagnostics developed by Retooling Task Force.
Progress and retooling needs as perceived by developers Retooling Task Force work planning meeting January 2008 Dr Giorgio Roscigno CEO – FIND.
1 |1 | Implementing HIV and TB Diagnostics in Resource Cape Town, South Africa, September 23 rd, 2014 New diagnostic technologies in development and target.
Implementation of Diagnostics in Resource-Limited Settings Amy Piatek Global Health Bureau, Office of Health, Infectious Diseases & Nutrition U.S. Agency.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
World Health Organization TB Case Definitions
Nucleic Acid Amplification Test for Tuberculosis
Systematic TB Screening: Philippine Experience The 9th Technical Advisory Group and National TB Program Mangers meeting for TB control in the Western Pacific.
GUIDELINES & TOOLS for HOSPITAL DOTS LINKAGE (HDL)
Advocacy for TB POC Diagnostic Javid Syed TB/HIV 15th Core Group Meeting Nov 3-4, Geneva.
World Health Organization, Western Pacific Regional Office Session 7 Empowering patients / civil society organizations Dr Cornelia Hennig Stop TB and Leprosy.
COUNTRY XEPERIENCE AND RESPONSE TO MDR AND XDR TUBERCULOSIS PRESENTED AT THE WHO TB/HIV PLANNING MEETING, ADDIS ABBABA, 11-12, NOVEMBER 2008 BY MS GUGU.
National TB/ Leprosy Programme Manager
Tools for HIV/TB Integration and the Civil Society Experience Carol Nawina Nyirenda Executive Director Community Initiative for Tuberculosis, HIV/AIDS.
Molecular methods for TB drug resistance testing: what is needed? Experience from Khayelitsha, Cape Town, South Africa Helen Cox, PhD, Burnet Institute.
Xpert in the diagnostic algorithm of pulmonary TB in adult patients who are neither high risk for HIV, nor high risk for MDR-TB Preparations for the global.
Integrating HIV and TB services : operational research issues TB/HIV workshop TAC/TAG June 2006 MÉDECINS SANS FRONTIÈRES SOUTH AFRICA UNIVERSITY OF CAPE.
Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,
Innovation in TB control: what’s in it for the field? Peter C.F.M. Gondrie, MD, MPH Executive Director
Downloaded from Accelerate scaling up of TB/HIV activities in Tanzania Dr. N.G.SIMKOKO WHO/NTLP - Tanzania.
Improving TB-DM Care in the Pacific: Partnerships and Progress R. Brostrom, MD-MSPH Hawaii TB Control Branch Chief Regional TB Field Medical Officer, CDC-DTBE.
Global Plan to STOP TB: Diagnostics WG Jane Cunningham Medical Officer WHO/TDR/PDE Secretariat STOP TB Diagnostics Working Group.
Tuberculosis Research of INA-RESPOND on Drug-resistant
TASK FORCE ON RETOOLING STOP TB PARTNERSHIP Cape Town November 2007.
WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
CLINICAL DIAGNOSTIC TB LABORATORY Alexander Sloutsky, Director University of Massachusetts Supranational Reference TB Laboratory Boston, MA.
TB PUBLIC-PRIVATE MIX DOTS Dr. Team Bakkhim Deputy Director CENAT Intercontinental Hotel 7 th November, 2012 NATIONAL FORUM ON PUBLIC-PRIVATE PARTNERSHIP.
Experience with Tb diagnostics and Scale up of services Botswana, Nigeria, and Tanzania Ernest Ekong, MD,MPH National Clinical Coordinator Harvard PEPFAR.
Project Goals  Support the National Tb Program (NTP)  Developed National Guidelines for prevention and control of Tb  Developed guidelines for treating.
FIND Ongoing Activities What’s in the pipeline for Rapid DST? WHO Stop TB Department Supranational Reference Laboratory Network Meeting Paris, October.
Smear negative TB and HIV: urgent research priorities to inform a rolling global policy Haileyesus Getahun, MD, MPH, PhD Stop TB Department WHO/HQ.
1 TB Diagnostics* Vinand M Nantulya *Presentation at TAC/TAG First Africa Region TB/HIV Advocacy, June 2006, Cape Town, South Africa.
Unit 12: Reporting & Recording Botswana National Tuberculosis Programme Manual Training for Medical Officers.
June 30, 2010 TB Program Thailand MOPH – U.S. CDC Collaboration TB Project Implementation: Impact on NTP?
Update of the Global Plan to Stop TB TB/HIV Working Group Meeting Geneva, November 2009 Christian Lienhardt.
Revision of new diagnostics for TB
1 DEWG meeting October 2009 Human Resource Development for TB Control (HRD-TB) Sub Group within the DEWG of the Stop TB Partnership. Wanda Walton.
Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva, Switzerland TB prevention, care and control, : Framing global and WHO strategic.
TB Control Measures: From development and endorsement to adoption and implementation Léopold Blanc TBS Stop TB department WHO Christy Garcia University.
The Stop TB Partnership Task Force on “Retooling” Update for the Working Groups Annual Meeting Vinand Nantulya & Nina Schwalbe, co-chairs of Task Force.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
The role of prevalence surveys in measuring the burden of TB, progress in TB control and improving early case detection Ikushi Onozaki WHO/STB/TBS Global.
TB infection control and prevention of XDR Group II.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
Revolutionizing TB Control with Innovation in New Diagnostics Dr Giorgio Roscigno Chief Executive Officer, FIND Reversing the Tide: the End of Tuberculosis,
Dr Justin O’Grady. Zambia is a high burden TB and high HIV setting 44,154 TB cases notified in 2010 – incidence of 462/100,000 pop Approx 48% of pulmonary.
Measures to Decrease TB Prevalence in the Barents Region Andrey O. Maryandyshev Elena I. Nikishova Dmitry V. Perkhin.
Roundtable. Detection and treatment of TB Andrew Black.
Rauni Ruohonen FILHA Priorities of TB control in penitentiary care.
TB infection control in the era of MDR and XDR TB Haileyesus Getahun Stop TB Department WHO/HQ.
New WHO algorithm to prevent TB deaths in seriously ill patients with HIV Yohhei Hamada TB/HIV and Community Engagement.
This is an archived document.
Stop TB Partnership Secretariat (TBP)
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
Screening and diagnosing TB in PLHIV: Challenges and ways forward
Conclusions and recommendations – first draft
DOTS EXPANSION AND BEYOND DOTS World Health Organization
Deciphering TB Lab Reports
5th DEWG meeting Conclusions
Dr. Kenneth L. Chebet Director NASCOP/NLTP Division Kenya
Fabio Scano IUATLD Conference Paris, 2003
Monitoring and Evaluation: A Review of Terms
Presentation transcript:

Barbara Laughon NIAID, NIH Report of TB/HIV Diagnostics Task Force

TB/HIV Diagnostics Task Force STOP –TB WG on New Diagnostics reorganized with liaisons from other WG A statement of needs requested from the TB/HIV group Task force formed to discuss, establish communications with NDWG and FIND, and report back on the latest information on availability of improved diagnostics for TB/HIV co-infected.

FIND is a public/private partnership established in 2003 as a Geneva based non-profit foundation and Chair of the NEW DIAGNOSTICS WG. The New Diagnostics WG was established in 2001 to promote the development and adoption of new and modified diagnostic products. The Chair of the WG is the Chief Executive Officer of the Foundation for Innovative New Diagnostics (FIND) and the secretariat is provided by the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR).

New Diagnostics Working Group Giorgio Roscigno Andrew Ramsay Jean-Francois de Lavison Arend Kolk Vaira Leimane Savita Luka Carol Nyirenda Mark Perkins John Ridderhof Felix Salaniponi Francis Varaine

Project phases & milestones PHASES Milestones Output FIND Feasibility Contra ct phase Develo pment phase Evalu ation phase Demonst ration phase Glob al Polic y Customer Requirements Specifications 8 Natio nal Practi ce Imp act Customer support document WHO guidelines Effectiveness Efficacy Product in box Effectiveness & Access Registration Customer support document Marketing plan Feasibility Contra ct phase Develo pment phase Evalu ation phase Demonst ration phase Glob al Polic y Customer Requirements Specifications 8 Natio nal Practi ce Imp act Customer support document WHO guidelines Effectiveness Efficacy Product in box Effectiveness & Access Registration Customer support document FIND PARTNERS Marketing plan Partnership Strategy

TB/HIV Diagnostics Task Force Formed in October 2007 Series of conference calls inviting FIND staff and others with expertise Statement of needs drafted (see report) FIND presented at the RTTF meeting Geneva 16 January and in Washington 22 January 2008 NDWG released revised pipeline March 2008 (

Progress and retooling needs as perceived by developers Retooling Task Force work planning meeting January 2008 Dr Giorgio Roscigno CEO – FIND

FIND has a rich set of products in the pipeline intended for the different levels of the health system which are developed and evaluated following a well- defined process from feasibility onwards… FIND’s perspective:

1. Early diagnosis of active tuberculosis in people living with HIV is critical - TB with HIV infection can be rapidly fatal. a. Point-of-service diagnosis is needed as HIV+ individuals may seek care at sites beyond traditional TB program facilitates. Laboratories may not be equipped with TB-trained personnel and referral can be inefficient and unreliable. b. The costs of special TB tests (chest x-ray, microscopy, culture, etc.) at HIV clinics may be charged directly to the patients creating financial barriers for individuals. c. Some HIV+ individuals may present with pauci-bacillary or negative sputum. Immediate improvements in the overall quality control of smear laboratories using existing technology could greatly improve smear sensitivity and care. More sensitive fluorescence equipment may be needed. The TB/HIV Working Group Task Force Summary of Special Diagnostic Issues for TB/HIV co-infection

1. Early diagnosis of active tuberculosis (continued). d. Some HIV+ individuals may present with extrapulmonary TB requiring early clinical suspicion and special sampling methods - aspiration, tissue samples. Appropriate laboratory processing may not be timely or available at point-of-service. e. Availability of rapid culture services cannot be delayed by transfer to a central laboratory. Peripheral laboratories need increased sensitivity for detection in TB/HIV patients. The TB/HIV Working Group Task Force Summary of Special Diagnostic Issues for TB/HIV co-infection

2. Early detection of XDR (MDR) - TB for initiation of appropriate therapy needs to occur simultaneously with TB diagnosis. a. Availability of culture to support drug susceptibility testing cannot be delayed in rapidly progressing TB. b. Manual MGIT or agar plating or MODS systems could be implemented at point-of-service HIV sites. c. Existing line probe assays to detect TB and RIF drug resistance in sputum should be systematically evaluated in TB/HIV settings. The TB/HIV Working Group Task Force Summary of Special Diagnostic Issues for TB/HIV co-infection

3. New diagnostic tests appropriate for TB/HIV co-infection will be needed to address these issues. Test formats recommended include: a. Lateral flow tests or dip sticks using easily accessible specimens such as urine, saliva, or blood. b. Line probe assays or other nucleic acid amplification assays that can integrate into laboratories already using PCR for HIV RNA copy numbers. c. Combined HIV and MTB testing in one product. d. Self-contained PCR test devices returning screening results during a clinical visit. The TB/HIV Working Group Task Force Summary of Special Diagnostic Issues for TB/HIV co-infection

Conclusions Improved TB diagnosis (including MDR and XDR) for PLHIV is topmost priority for TB/HIV WG. The development of new tools effective for PLHIV is long overdue and should be addressed as a matter of urgency.

TB/HIV Diagnostics Task Force Action Items Finalize a statement from TB/HIV WG chair regarding new diagnostics needs Continue to engage the New Diagnostics Working Group, especially in Geneva Request a focused meeting with FIND (Cairo, ASM, Geneva) Organize a workshop in the U.S. with technical researchers, chemists, Aby producers co-sponsored by TB/HIV, FIND, TAG, NIAID.